Cargando…

Nivolumab induced myxedema crisis

BACKGROUND: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxe...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Uqba, Rizvi, Humaira, Sano, Dahlia, Chiu, Jane, Hadid, Tarik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319087/
https://www.ncbi.nlm.nih.gov/pubmed/28239466
http://dx.doi.org/10.1186/s40425-017-0213-x

Ejemplares similares